secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116264
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q3 revenue $15.1M (+35% YoY); narrows FY2023 guidance to $57-60M
-------------------------------------------------------------------------

- Revenue of $15.1M, up 35% YoY, marking 11th straight quarter of ≥35% growth.
- OviTex hernia mesh now #1 biologic mesh in U.S. by unit volume.
- OviTex PRS revenue grew 46% YoY; commercial launch of Long-Term Resorbable variant.
- Q3 net loss $11.0M vs. $10.7M a year ago; cash $58.2M at quarter end.
- Updated FY2023 revenue guidance to $57-60M (38-45% YoY growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/0001104659-23-116264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923116264/tm2330287d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer